Aculys Pharma initiates collaboration with Ubie with the aim of building a “sleep ecosystem”
– a fact-finding survey of patients with sleep disorders to be conducted as a first step – Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo, Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, initiated a fact-finding survey about […]
Aculys Pharma Closes US$24 Million Series B Financing
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, today announced that it has raised a total of US$24 million in Series B Round with participation by […]
Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, announced that it has initiated a Phase 1 clinical trial of histamine H3 receptor antagonist / inverse agonist, pitolisant […]
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray), a nasal spray approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years of age and older. There are currently no approved nasal sprays available […]
Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2
Aculys Pharma, Inc. (“Aculys Pharma”), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, today announced the closing of a US$60 million Series A financing led by SoftBank Vision Fund 2 and joined by Catalys Pacific, HBM Healthcare Investments, Global Founders Capital, Sumitomo […]
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)